

Mechanisms of microRNA-mediated regulation of angiogenesis

Hong Shi^{1,2}, Peiying Li¹, Weimin Liang¹, Jun Chen^{2,3}, Yanqin Gao²

¹ Department of Anesthesiology of Huashan Hospital, Fudan University, Shanghai 200032, China, ²State Key Laboratory of Medical Neurobiology and Institutes of Brain Science, Fudan University, Shanghai 200032, China, ³Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Role of angiogenesis in stroke and the molecules and proteins involved in the process
 - 3.1. Role of angiogenesis in stroke
 - 3.2. Molecules and proteins involved in angiogenesis after stroke
 - 3.2.1. Endothelial progenitor cells and endothelial cells
 - 3.2.2. Molecules and proteins associated with angiogenesis
 - 3.2.2.1. VEGF and its receptors
 - 3.2.2.2. Angiopoietins and tie receptors
 - 3.2.2.3. Hypoxia-inducible factor 1
 - 3.2.2.4. Other factors in angiogenesis
 - 3.3. Traditional approaches to improve stroke recovery by enhancing angiogenesis
4. MicroRNA-mediated regulation of angiogenesis in oncology and non-brain angiogenesis
 - 4.1. MicroRNAs: biogenesis and mechanisms of action
 - 4.2. Dicer, Drosha and angiogenesis
 - 4.3. Individual microRNAs involved in oncology and non-brain angiogenesis
 - 4.3.1. MiR-15b and -16
 - 4.3.2. MiR-17-92 cluster
 - 4.3.3. MiR-126
 - 4.3.4. MiR-130a
 - 4.3.5. MiR-210
 - 4.3.6. MiR-221 and -222
 - 4.3.7. Let-7f
5. Potential therapeutic options via mediating associated microRNAs after stroke
 - 5.1. Inhibition of associated microRNAs
 - 5.2. Over-expression of associated microRNAs
6. Summary

1. ABSTRACT

Stroke is the second most common cause of death and consumes about 2-4% of total health-care costs worldwide. Although most studies have focused on neuroprotection during the past decades, current therapeutic options are still very limited. Recently scientists have intensified their work on neurorestorative therapies, including angiogenesis, which allow a far greater time window for improving neurological recovery. MicroRNAs have emerged as crucial players, regulating almost every cellular process investigated to date, and evidence of their role in the context of angiogenesis and stroke has been rapidly accumulating. The goal of this review is to summarize the mechanisms of microRNA-mediated regulation of angiogenesis and the implications for a novel molecular approach to enhance neurological recovery after stroke.

2. INTRODUCTION

Stroke is the second most common cause of death (1) and consumes 2-4% of total health-care costs worldwide (2, 3). On average, every 45 seconds someone in the United States has a stroke (4). With the population aging, the burden will increase greatly during the next 20 years, especially in developing countries (5). Advances have occurred in stroke treatment during the past decades, but current therapeutic options are still very limited. Recently scientists have intensified their work on neurorestorative therapies, including angiogenesis, with the aim of improving stroke recovery in a longer time window (6). Angiogenesis, always coupled with neurogenesis, could be interpreted as a natural defense mechanism, helping to restore oxygen and nutrient supplies to the affected brain tissue. It has been demonstrated that

angiogenesis is involved in functional recovery after ischemic stroke and correlates with longer survival (7-12).

MicroRNAs, 19-24 nucleotides, have emerged as key players regulating magnitude of gene expression in a variety of organisms (13). It is estimated that about 3% of human genes encode for microRNAs (14), and approximately 30% of mRNAs are regulated by them (14-17). MicroRNAs have been identified to participate in almost every cellular process investigated to date, and their dysregulation is also observed in different human pathologies involved in tumor, inflammation, and apoptosis (14, 18-23). Accumulated evidence from different laboratories suggests that microRNAs play a crucial role in the regulation of angiogenesis and stroke (22-30). Specific microRNAs have been identified in the angiogenic process (24, 31-64). Because of their distinct mechanisms of action, microRNAs represent a potential therapeutic target; it is possible that angiogenesis may be enhanced for stroke recovery by over-expressing or inhibiting associated microRNAs (24). Despite increasing evidence for the regulatory influence of microRNAs in angiogenesis, individual microRNAs involved in the process and the potential approaches of using microRNAs to enhance angiogenesis after stroke have not been previously evaluated. Therefore, this review summarizes the mechanisms of microRNA-mediated regulation of angiogenesis and implications for a novel molecular approach to enhance neurological recovery after stroke.

3. ROLE OF ANGIOGENESIS IN STROKE AND THE MOLECULES AND PROTEINS INVOLVED IN THE PROCESS

Time is brain for patients suffering stroke. The only approved effective drug, recombinant tissue plasminogen activator, must be administered within 4.5 hours after the onset of stroke in very carefully selected patients (65). Neurorestorative processes, which allow a far greater time window for improving neurological recovery, include angiogenesis, neurogenesis and synaptic plasticity (6). Increasing evidence suggests that angiogenesis, always coupled with neurogenesis, plays a key role in neurological recovery after stroke. Below we will summarize the role of angiogenesis in stroke, associated molecules and proteins, and traditional approaches.

3.1. Role of angiogenesis in stroke

Angiogenesis is a physiological process during development; however, during some pathological events such as stroke, endothelial cells become activated and angiogenesis ensues to provide conduits for blood flow (66). In addition, angiogenic vessels provide neurotrophic support to newly generated neurons. Thus, angiogenesis plays a crucial role in the recovery of blood flow in affected brain tissues. It has been suggested that greater microvessel density in the ischemic border correlates with longer survival in stroke patients (12). In addition, increased spontaneous vascularization during neurological recovery in the site of penumbra has been described (13, 14).

It has been demonstrated that endothelial cells surrounding the infarcted brain area start to proliferate as

early as 12–24 hours after stroke, and active angiogenesis takes place in human brain at 3–4 days following ischemic insult (67-70). It still remains unclear how long angiogenesis persists. Hayashi and colleagues reported that vessel proliferation continues more than 21 days following ischemic stroke (68).

3.2. Molecules and proteins involved in angiogenesis after stroke

Several molecules and proteins that change after stroke have been identified as playing a role in the angiogenic process. The following is a summary of the literature to date on molecular mechanisms and proteins associated with angiogenesis after stroke.

3.2.1. Endothelial progenitor cells and endothelial cells

The increase of circulating endothelial progenitor cells after acute ischemic stroke leads to good functional outcome and reduced infarct growth (71), and a lower concentration contributes to severe neurological impairments (72). Circulating endothelial progenitor cells can home to sites of neovascularization and differentiate into endothelial cells (73, 74).

Endothelial cell migration and proliferation involved in angiogenesis are associated with vascular remodeling in penumbra (75, 76). It has been demonstrated that endothelial cells surrounding cortical infarcted brain areas began to proliferate as early as 12 hours in different cerebral ischemic models (67, 68). Furthermore, intact and injured endothelial cells have different effects on neurogenesis (6, 8, 69, 77).

3.2.2. Molecules and proteins associated with angiogenesis

Increasing molecules and proteins have been shown to be involved in the angiogenic process following stroke, including vascular endothelial growth factor (VEGF), angiopoietins and tie receptors, hypoxia-inducible factor 1 (HIF1), and matrix metalloproteinases (MMPs).

3.2.2.1. VEGF and its receptors

VEGF, widely expressed in the normal brain, is the most important mitogen in the process of angiogenesis after stroke. An elevated level of VEGF expression in the infarcted hemisphere was observed as early as 3 hours after ischemic insult and continued up to 3 days (69) or even as much as 7 days following stroke (78, 79). VEGF is capable of promoting cerebral angiogenesis and improving oxygen and nutrient delivery to the affected brain tissue. Thus, VEGF has been shown to be neuroprotective in different animal models (78-83). VEGF has been demonstrated to exist in microvessels in penumbra and special types of cells in brain after stroke (78, 79, 84-87). These data suggest that VEGF is produced and secreted by these cells and binds to its receptors on nearby vascular endothelial cells to directly initiate an angiogenic response (79). The binding of VEGF to its receptors on the surface of endothelial cells activates intracellular tyrosine kinases and triggers multiple downstream signals that promote angiogenesis (76). Increased levels of VEGF have been identified in human brain and serum (88-90).

VEGF binds to its receptors (VEGFR-1 or VEGFR-2) and then leads to receptor dimerization, signal transduction and thus angiogenesis (76). VEGFR-1 expressed in distinct vascular beds increases after ischemic stroke. This indicates its inert “decoy” effects by binding VEGF, subsequently regulating the availability of VEGF for activation of VEGFR-2 (69, 76, 79, 85, 91). VEGFR-2 is expressed on almost all endothelial cells, and mediates the majority of the downstream angiogenic effects of VEGF, including endothelial cell proliferation, invasion, migration and survival (91). Up-regulation of VEGFR-2 follows an ischemic insult (69, 78, 87) for up to 7 days (69).

Notably, a deleterious effect of VEGF in ischemic stroke has been observed (92). Blood vessel growth initiated by VEGF alone stimulates the formation of an immature, leaky vasculature, which may contribute to edema and worsen cerebral injury. Timing, dose and route of administration are likely to be important in dictating the balance of favorable versus detrimental effects associated with VEGF therapy for acute stroke (93).

3.2.2.2. Angiopoietins and tie receptors

The angiopoietin family consists of four members (Ang-1-4). Both Ang-1 and Ang-2 levels increased in affected brain tissue after an ischemic insult, up to 28 days (94-97). In concert with VEGF, Ang-2 promotes angiogenesis (98). It blocks the stabilization and maturation function of Ang-1 and induces loosening of endothelial cell/pericyte contacts, thus allowing vessels to convert into a more plastic state (76). However, Ang-2 leads to endothelial death and vascular regression in the absence of VEGF (98).

Tie-1 and Tie-2 are two receptor tyrosine kinases of angiopoietins. All four angiopoietins have been identified as ligands for Tie-2, which is majorly expressed on endothelial cells. Natural ligands for the Tie-1 receptor have not been found (76). Tie-1 was expressed in ischemic lesion as early as 2 hours after ischemic insult (99). Lin and his colleagues described a biphasic expression pattern of Tie-1 and Tie-2 following an ischemia-reperfusion model. A few hours after the insult they observed an up-regulation of both receptors in capillaries inside the ischemic cortex. The second peak started at 3 days and continued to 7 days after ischemic stroke (100).

3.2.2.3. Hypoxia-inducible factor 1

Hypoxia-inducible factor 1 (HIF1), the first characterized member of the HIF family, is a heterodimer composed of subunits HIF1- α and HIF1- β . Expression of HIF1- α may be induced by a number of pathways, and its degradation is highly sensitive to O₂ levels. Intracellular HIF1- α , called a master switch for hypoxic gene expression, is experimentally undetectable under normoxic conditions. However, it rapidly accumulates in the cell nucleus and triggers gene expression during hypoxia (101-103). In addition, microRNA profiles of cancer cells revealed that at least a subgroup of hypoxia-regulated microRNAs was induced by

HIF, supporting the key role of HIF as a transcription factor for microRNA expression during hypoxia (104).

3.2.2.4. Other factors in angiogenesis

Increasing numbers of molecules and proteins have been identified as being involved in angiogenesis following stroke. MMPs collectively regulate the angiogenic processes of sprout initiation, tube formation and stability, and capillary regression (105, 106). Recently, Lee and his colleagues (107) reported that VEGF can induce MMP-9 activities and focal angiogenesis.

Neuropilins (comprised of NP-1 and NP-2) appear to increase binding of VEGF isoforms to VEGFR-2, but decrease binding to VEGFR-1 (108, 109). Both NP-1 and NP-2 mRNA were up-regulated after ischemic stroke (110, 111).

Placenta growth factor is a ligand of VEGFR-1 that specifically potentiates the angiogenic response to VEGF by activation of VEGFR-1. Its mRNA and protein were both up-regulated in vessels in affected brain tissue with a peak of expression at 3 days after an ischemic insult (111). Moreover, elevated expression of erythropoietin by hypoxia has been identified (112-115).

3.3. Traditional approaches to improve stroke recovery by enhancing angiogenesis

For patients with acute stroke, interventions of proven benefit include management in a stroke care unit, intravenous tissue plasminogen activator within 4.5 hours or aspirin within 48 hours of stroke onset, and decompressive surgery for supratentorial malignant hemispheric cerebral infarction (2, 65). However, time is brain to the patients' functional recovery. Recently scientists have intensified their work on different approaches beyond the hyperacute phase of stroke. Angiogenesis, always coupled with neurogenesis and synaptogenesis, is one of the neurorestorative processes (42). The induction of angiogenesis, primarily in the ischemic boundary zone, enhances oxygen and nutrient supply to the affected tissue. Additionally, the generation of new blood vessels facilitates highly coupled neurorestorative processes which in turn lead to improved functional recovery (76).

There are several methods to enhance angiogenesis for improving stroke recovery, including physical activity, pharmacological approaches and stem cells. Physical training promotes angiogenesis by up-regulating mRNA levels of the angiopoietin family, VEGF and increased phosphorylation of eNOS for improving long-term stroke outcome (116-118). A large variety of agents can also boost angiogenesis after cerebral ischemia, including VEGF, phosphodiesterase type-5 inhibitors, heparin-binding epidermal growth factor-like growth factor, hepatocyte growth factor, fibroblast growth factor-2, adrenomedullin, HMG-CoA reductase inhibitors or “statins,” kallikreins, erythropoietin, nitric oxide donors, angiotensin 2 type 1 receptor blockade, and granulocyte colony stimulating factor (76).




Figure 1. MicroRNAs: biogenesis and mechanisms of action. MicroRNAs are initially transcribed as pri-microRNAs by RNA polymerase 2, before being processed by Drosha to generate pre-microRNAs which are exported from the nucleus into the cytoplasm where they are further processed by Dicer to form the mature microRNA. Mature microRNAs post-transcriptionally regulate target gene expression by forming hybrid complexes with target mRNAs in their 3'UTR, and subsequently repress translation or lead to target mRNA cleavage, depending on the degree of complementarity that exists between the microRNA and its targets.

Recent work has focused on cell transplantation as a therapeutic option following ischemic stroke, and the observed improvement has been attributed to the release of trophic factors, possibly promoting endogenous repair mechanisms, reducing cell death and stimulating neurogenesis and angiogenesis (119). An increased understanding of the biology of stem cells offers potential in the treatments for ischemic stroke. Moreover, transplanted stem cells have been involved in the release of endogenous growth factors stimulating vasculogenesis (120). Cell replacement therapy in ischemic stroke from both clinical and experimental points of view presents considerable variability in outcome. Functional improvement and long-term outcome can be influenced by the properties of stem cell type, the route of cell administration, and time interval following the ischemic insult (119).

4. MICRORNA-MEDIATED REGULATION IN ONCOLOGY AND NON-BRAIN ANGIOGENESIS

Since the 1993 discovery of lin-4 in *C. elegans* (121,122), thousands of microRNA sequences have been noted in animals, plants and even viruses. As this inventory of known microRNAs continues to increase, it is becoming evident that microRNAs regulate a variety of important cellular functions. Accumulated data show an important

role of microRNAs in regulating angiogenesis of different pathologic processes such as tumor, inflammation, and apoptosis (14-23).

The expression of microRNAs in endothelial cells has been demonstrated in different labs (123, 124). The highly expressed microRNAs include miR-15b and -16, -20, -21, -23a and -23b, -24, -29a and -29b, -31, -99a, -100, -103, -106, 125a and -125b, -126, -130a, -181a, -191, -221, -222, -320, let-7, let-7b and let-7c (123-125). However, few specific targets and functions involved in angiogenesis have been identified.

4.1. MicroRNAs: biogenesis and mechanisms of action

Mature microRNA is part of a 60-80-nucleotide stem-loop structure contained within the pri-microRNA. The first step in microRNA biogenesis occurs in the nucleus and requires the excision of this hairpin structure by a complex called Microprocessor (Figure 1). This complex contains the RNase 3-like Drosha enzyme and the RNA binding protein DGCR8/Pasha (126). The excised hairpin, now called pre-microRNA, is exported to the cytoplasm by a protein heterodimer consisting of the transport factor Exportin-5 and its cofactor Ran (127). In the cytoplasm, Dicer, an RNase 3 enzyme, excises the pre-microRNA to a 19- to 24-base-pair product. The product is able to be incorporated into the RNA-induced silencing

complex (RISC) (128-134). The RISC, in turn, is capable of using the “seed sequence” of the microRNA to recognize complementary messenger RNA (mRNA) transcripts for degradation or translational silencing (15, 130, 135).

The microRNA is now ready to direct its activities on target mRNA by binding microRNA responsive elements usually located in the 3'UTR of the transcript (Figure 1). This association may result in either cleavage or translational repression of the target mRNA, depending on the degree of base-pairing between the microRNA and the responsive element. Perfect complementarity generally results in target mRNA cleavage, whereas imperfect base-pairing leads to translational repression (136). The interaction between the microRNA and its target mRNA occurs between the 5'UTR of the microRNA to the 3' UTR region of the mRNA by a matching seed element in the microRNA. Utilizing these data, one microRNA can regulate hundreds of genes (137) and, at the same time, one mRNA can be regulated by a number of microRNAs.

4.2. Dicer, Drosha and angiogenesis

Because Dicer and Drosha are essential for microRNA processing, blocking Dicer or Drosha expression might be expected to cause the down-regulation of most microRNAs (138). Studies have shown that Dicer plays a crucial role in angiogenesis *in vivo* and *in vitro*. Reduction of microRNA levels *via* Dicer silencing strongly impacts the functions of endothelial cells *in vitro*, which suggests a key role for microRNAs in angiogenesis (123, 124). Reduction of endothelial microRNAs by cell-specific inactivation of Dicer attenuates postnatal angiogenic responses to a variety of stimuli, including exogenous VEGF, tumors, limb ischemia and wound healing (42). Depletion of Dicer was found to impair the development of capillary-like structures and to show an anti-proliferative effect (139, 140). Furthermore, knockdown of Dicer expression has been shown to cause profound dysregulation of angiogenesis-related genes (140, 141).

In contrast to Dicer, genetic silencing of Drosha expression in endothelial cells with siRNA resulted in a significant reduction in capillary sprouting and tube formation *in vitro*, although the reduction was much smaller than that resulting from genetic silencing of Dicer. Drosha siRNA did not block angiogenesis *in vivo*. The difference between the effects of siRNA-mediated knockdown of Dicer and those of Drosha on capillary sprouting, migration, proliferation and *in vivo* angiogenesis might be due to the involvement of Dicer in other cellular processes, such as regulation of heterochromatin formation, or an alternative Drosha-independent microRNA processing pathway that could compensate for the loss of Drosha (123, 124, 142).

4.3. Individual microRNAs involved in oncology and non-brain angiogenesis

Although a number of studies have emphasized the importance of the microRNA pathway in several aspects of the angiogenic process, the majority do not

provide information regarding the functions of specific microRNAs. Studies aimed at elucidating the role of individual microRNAs in the regulation of angiogenesis in oncology and non-brain angiogenesis are increasingly being performed, and most of the examples that illustrate principles of microRNA function in angiogenesis are presented here.

4.3.1. MiR-15b and -16

An association between microRNAs and human cancer was first reported in 2002 when it was shown that miR-15a and miR-16a map to chromosome 13q14, a region deleted at high frequency in chronic lymphocytic leukemia (CLL) (143). MiR-15 and -16 enhance tumor angiogenesis, tumor cell survival, and growth by targeting tumor suppressors (123, 144). Both microRNAs have been shown to induce apoptosis of leukemic cells by targeting the anti-apoptotic protein Bcl-2, to block cell cycle progression and to be frequently down-regulated in chronic lymphocytic leukemia (145, 146).

Although the direct effects of miR-15b and -16 on endothelial cells have not been determined, both microRNAs are down-regulated by hypoxia and regulate the expression of VEGF in a carcinoma cell line (123, 138, 144). In addition, miR-15b and -16 have been shown to control the expression of VEGF, a key pro-angiogenic factor (87). These data indicate that hypoxia-induced reduction of miR-15b and -16 contributes to an increase in VEGF (138).

4.3.2. MiR-17-92 cluster

A potent angiogenesis-promoting activity has been attributed to the miR-17-92 cluster (42, 64, 147, 148-153). In the human genome, the miR-17-92 cluster encodes six microRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1) which are tightly grouped within an 800-base-pair region of human chromosome 13.

The levels of miR-17, -18a, and -20a in quiescent endothelial cells were very low, and VEGF induction of these microRNAs suggests that they may regulate the proliferative actions of VEGF. Over-expression of these microRNAs in Dicer-knockdown endothelial cells rescues the defect in cell proliferation and cord formation (42), suggesting that VEGF-induced proliferation and morphogenesis are mediated in part by miR-17-92 cluster activation. MiR-17-92 cluster knockdown partly restores Tsp1 and CTGF expression. Furthermore, transduction of Ras-only cells with a miR-17-92-encoding retrovirus attenuated Tsp1 and CTGF levels. Cells transduced with miR-17-92 cluster, also known as Oncomir-1, formed larger, better-perfused tumors. These findings establish a role for the miR-17-92 cluster in non-cell-autonomous Myc-induced tumor vascular biology (46, 64, 154). When components of this cluster are over-expressed in tumor cells, they specifically target anti-angiogenic proteins containing thrombospondin type 1 repeats such as Tsp1, connective tissue growth factor, and SPARC (64).

4.3.3. MiR-126

The best-characterized endothelial cell-specific microRNA is miR-126 (43, 44, 155). In mammals, it is

encoded by intron 7 of the EGF-like domain 7 (Egfl7) gene also known as VE-statin (156, 157). Indeed, the expression of Egfl7 and miR-126 largely matched that of endothelial cell markers during embryoid body formation, being highly enriched in Flk1-positive vascular progenitors at embryonic day 4 and in mature CD31- expressing endothelial cells at embryonic day 7 (43).

MiR-126 has been identified as enriched in tissues with a high vascular component in both mouse and zebrafish (158, 159). *In vitro*, miR-126 regulates many aspects of endothelial cell biology, including cell migration, organization of the cytoskeleton, capillary network stability and cell survival (43). MiR-126 has an increased expression in endothelial cells, where it sustains pro-angiogenic factor signals through SPRED1 and PI3K regulatory subunit 2 (PI3KR2) repression (43), and its down-regulation in tumor cells contributes to abnormal proliferation (160).

MiR-126 regulates the response of endothelial cells to VEGF (43) and FGF (44), and developmental angiogenesis *in vivo* (44). It was shown that knockdown of miR-126 in zebrafish resulted in a loss of vascular integrity and hemorrhage during embryonic development (43). A targeted deletion of miR-126 (miR-126^{-/-}) in mice results in similar effects, including leaky vessels, hemorrhaging, and partial (~40%) embryonic lethality. MiR-126^{-/-} mice that survived to adulthood appeared normal, indicating the important effect of miR-126 in vascular integrity during embryogenesis (44). MiR-126-targeted deletion reduces survival after myocardial infarction, since neovascularization is essential for cardiac repair (44). These findings illustrate that a single microRNA can regulate vascular integrity and angiogenesis, providing a new target for either pro- or anti-angiogenic therapies (161).

4.3.4. MiR-130a

The pro-angiogenic miR-130a is expressed at low levels in quiescent HUVEC and is up-regulated in response to fetal bovine serum (162). MiR-130a is a regulator of the angiogenic phenotype of endothelial cells through its ability to modulate the expression of the anti-angiogenic homeobox proteins GAX (growth arrest homeobox) and HoxA5. MiR-130a antagonizes the inhibitory effect of GAX on endothelial cell proliferation, migration, and tube formation and the inhibitory effects of HoxA5 on tube formation (162). The regulation of angiogenesis by hypoxia is an important component of homeostatic mechanisms that link vascular oxygen supply to metabolic demand (163).

4.3.5. MiR-210

MiR-210 is induced by hypoxia in endothelial cells (164). Over-expression of miR-210 in normoxic endothelial cells stimulates the formation of capillary-like structures and VEGF-driven migration, whereas its blockade inhibits the formation of capillary-like structures and decreases the migration in response to VEGF. The modulation of endothelial cell responses to hypoxia is mediated *via* the regulation of the receptor tyrosine-kinase ligand Ephrin-A3 (164). Although the importance of Eph-

A2 in the regulation of angiogenesis and VEGF signaling has been reported, little is known yet about the specific role of Eph-A3. However, these data suggest that down-regulation of Eph-A3 is necessary for the miR-210-mediated stimulation of capillary-like formation and endothelial cell chemotaxis in response to VEGF and may contribute to modulating the angiogenic response to ischemia (165).

4.3.6. MiR-221 and -222

MiR-221/-222 over-expression in Dicer-knockdown endothelial cells restored the elevated eNOS protein levels eNOS induced by after Dicer silencing (125). NO synthesized by eNOS is necessary for endothelial cell survival, migration and angiogenesis (166). However, prediction sites for these microRNA were not found in eNOS 3'UTR, suggesting that the regulation of eNOS protein levels by miR-221/222 is likely to be indirect. Collectively, these reports suggest an anti-angiogenic action for these microRNAs, making them possibly a potential tool to block angiogenesis (167). In addition, loss of miR-221 and miR-222 in endothelial cells sustains the proliferative and angiogenic properties of KIT, and regulates CKI p27 (167), increasing cell proliferation and enhancing their metastatic potential (168,169).

4.3.7. Let-7f

Members of the let-7 family are enriched in endothelial cells and are also highly expressed in normal rat carotid arteries (123-125, 154), suggesting that these microRNAs indeed belong to the specific microRNA signature of the vasculature. With regard to angiogenesis, the highly expressed let-7f exert pro-angiogenic effects as evidenced by the blockade of *in vitro* angiogenesis with 2'-O-methyl oligonucleotide inhibitors (123). Additional pro-angiogenic microRNAs include let-7f, as assessed by the blockade of *in vitro* angiogenesis by 2'-O-methyl oligonucleotide inhibitors (123, 139).

Other microRNAs that were implicated in promoting angiogenesis include miR-378 (170), miR-27b, and let-7f (123), while microRNAs may also act *via* interconnected complex networks.

5. POTENTIAL THERAPEUTIC OPTIONS *VIA* MEDIATING ASSOCIATED MICRORNAS AFTER STROKE

To date, there is no direct evidence to show that microRNA-mediated angiogenesis could reduce the infarct volume or improve functional outcomes after stroke. However, microRNAs represent an attractive potential therapeutic target since enhancement of angiogenesis has been identified as an effective therapeutic strategy and microRNAs are involved in the angiogenic process. Thus, selective regulation of particular microRNAs targeting angiogenesis is a promising prospect for stroke. The synthesis, maturation and activity of microRNAs can be manipulated with various oligonucleotides that encode the sequences complementary to mature microRNAs (171). Over-expression of microRNAs can be induced by using either synthetic microRNA mimics or chemically modified

oligonucleotides (130). Conversely, microRNAs can be silenced by antisense sequences (synthetic analogues of microRNAs) (172, 173). Such manipulation may control angiogenesis and have potential as a new therapy for ischemic stroke. It is important to seek routes to interfere with microRNAs and to develop these as novel cerebral ischemia therapies.

5.1. Inhibition of associated microRNAs

MicroRNA antisense oligonucleotides provide an effective way to inhibit the activity of a microRNA involved in angiogenesis. The fact that microRNAs bind to their mRNA targets by Watson-Crick base-pairing indicates that a potential effective method of inactivating pathological microRNAs is to use an oligonucleotide complementary to the microRNA that effectively competes with the mRNA target. This method could avoid down-regulation of important targets that promote the stimulation of gene expression (172, 174, 175). A number of groups have shown that vectors expressing microRNA target sites can be used to saturate an endogenous microRNA and prevent it from regulating its natural targets. This technology, which has been described using the terms *decoy*, *sponge*, *eraser*, *antagomir*, *anti-miRs* and *knockdown* (176-180), has utilized a variety of gene delivery systems, including plasmids as well as vectors based on adenoviruses, retroviruses and lentiviruses.

The use of antisense sequences in cultured cells has been successful; however, the key development was chemical modification of microRNA inhibitors for *in vivo* utility. The large body of research undertaken during the development of antisense therapeutics has led to effective strategies for the pharmacological delivery of nucleic acids, facilitating the development of microRNA therapeutics (181). Three different chemical modifications have been carried out to fulfill the inhibition of microRNA function *in vivo*. One class of antisense is conjugated to cholesterol (antagomiR) to facilitate cellular uptake. Other classes use oligonucleotides with locked nucleotide acid (LNA anti-miRs) or 2-O-methoxyethyl phosphorothioate (2'-MOE) modification (172,174,175). Studies have revealed that inhibition of miR-17-92 cluster activity is associated with angiogenesis (64, 182).

5.1.2. Over-expression of associated microRNAs

Alternatively, microRNA mimics (double-stranded oligonucleotides designed to simulate the function of endogenous mature microRNAs) may induce target mRNA down-regulation and thereby diminish gene expression (183). For example, over-expression of miR-15 and -16 might be an attractive anti-tumor strategy that could target tumor cell survival and proliferation and block VEGF-mediated angiogenesis (138).

Despite the advantages of microRNA technology, this new therapeutic approach has limitations. A high vector copy number or strong expression of the target-bearing transcript is needed, and this can be difficult to achieve in some cell and tissue types for the cell/tissue specificity (167). In addition, modifying a viral protein can have a negative impact on both the stability of the virus and

its ability to infect and replicate in the desired tissue, and some bystander infection of other tissues is difficult to avoid (183). Furthermore, the regulatory actions mediated by microRNAs are complex, and the same microRNA can cause the opposite biological effect depending on the context. Thus, despite the promise of the early studies, we must recognize that our still-limited understanding of microRNA biology and function caution us to move carefully towards a clinical translation of these new strategies.

6. SUMMARY

Time is brain for patients suffering stroke. Angiogenesis, always coupled with neurogenesis and synaptogenesis, leads to improved functional recovery after acute injury, and microRNAs have been suggested to be involved in the regulation of angiogenesis and stroke. In the present review, we have summarized the role of microRNAs in the regulation of angiogenesis and their potential therapeutic function after stroke. Although experimental microRNA therapy results look promising, they must be validated through studies involving different cohorts of patients before they can be introduced into clinical practice.

7. ACKNOWLEDGEMENTS

This review was supported by the Natural Science of Foundation of China (30870794 and 30772079) and the Open Research Fund Program of the Institutes of Brain Science, Fudan University.

8. REFERENCES

1. Christopher J L Murray, Alan D Lopez: Mortality by cause for eight regions of the World: Global Burden of Disease Study. *Lancet* 349, 1269-1276 (1997)
2. American Heart Association: Heart and Stroke Facts Statistics: Dallas: American Heart Association. (1997)
3. Helen M Dewey, Amanda G Thrift, Cathy Mihalopoulos, Robert Carter, Richard AL Macdonell, John J McNeil, Geoffrey A Donnan: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). *Stroke* 32, 2409-2416 (2001)
4. American Heart Association: Heart and Stroke Facts Statistics: Dallas: American Heart Association (2006)
5. Geoffrey A Donnan, Marc Fisher, Malcolm Macleod, Stephen M Davis: Stroke. *Lancet* 371, 1612-1623 (2008)
6. Jieli Chen, Michael Chopp: Neurorestorative treatment of stroke: cell and pharmacological approaches. *NeuroRx* 3, 466-473 (2006)
7. Caroline Leventhal, Shahin Rafii, Dahlia Rafii, Abraham Shahar, Steven A Goldman: Endothelial trophic support of neuronal production and recruitment from the

adult mammalian subependyma. *Mol Cell Neurosci* 13, 450–464 (1999)

8. Par Thored, James Wood, Andreas Arvidsson, Jorg Cammenga, Zaal Kokaia, Olle Lindvall: Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. *Stroke* 38, 3032–3039 (2007)

9. Hua Teng, Zheng Gang Zhang, Lei Wang, Rui Lan Zhang, Li Zhang, Dan Morris, Sara R Gregg, Zhenhua Wu, Angela Jiang, Mei Lu, Berislav V Zlokovic, Michael Chopp: Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. *J Cereb Blood Flow Metab* 28, 764–771 (2008)

10. Jerzy Krupinski, Jozef Kaluza, Pat Kumar, Shant Kumar, JM Wang: Role of angiogenesis in patients with cerebral ischemic stroke. *Stroke* 25, 1794–1798 (1994)

11. Ling Wei, Joseph P Erinjeri, Carl M Rovainen, Thomas A Woolsey: Collateral growth and angiogenesis around cortical stroke. *Stroke* 32, 2179–2184 (2001)

12. Shahin Rafii, David Lyden: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. *Nat Med* 9, 702–712 (2003)

13. Victor Ambros: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. *Cell* 113, 673–676 (2003)

14. Stefanie Sassen, Eric A. Miska, Carlos Caldas: MicroRNA: implications for cancer. *Virchows Arch* 452, 1–10 (2008)

15. Benjamin P Lewis, Christopher B Burge, David P Bartel: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120, 15–20 (2005)

16. Jan Kruger, Marc Rehmsmeier: RNAhybrid: microRNA target prediction easy, fast and flexible. *Nucleic Acids Res* 34, W451–W454 (2006)

17. Neil R Smalheiser, Vette I Torvik: Complications in mammalian microRNA target prediction. *Methods Mol Biol* 342, 115–127 (2006)

18. Natascha Bushati, Stephen M Cohen: microRNAs in neurodegeneration. *Curr Opin Neurobiol* 18, 292–296 (2008)

19. Aurora Esquela-Kerscher, Frank J Slack: Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer* 6, 259–269 (2006)

20. Eva van Rooij, Eric N Olson: MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. *J Clin Invest* 117, 2369–2376 (2007)

21. Yasuhiro Tomaru, Yoshihide Hayashizaki: Cancer research with non-coding RNA. *Cancer Sci* 97, 1285–1290 (2006)

22. Ranjan J Perera, Animesh Ray: MicroRNAs in the search for understanding human diseases. *BioDrugs* 21, 97–104 (2007)

23. Seungil Ro, Chanjae Park, David Young, Kenton M Sanders, Wei Yan: Tissue-dependent paired expression of miRNAs. *Nucleic Acids Res* 35, 5944–5953 (2007)

24. Chandan K Sen, Gayle M Gordillo, Savita Khanna, Sashwati Roy: Micromanaging Vascular Biology: Tiny MicroRNAs Play Big Band. *J Vasc Res* 46, 527–540 (2009)

25. Kandiah Jeyaseelan, Kai Ying Lim, Arunmozhiarasi Armugam: MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. *Stroke* 39, 959–966 (2008)

26. Ashuthosh Dharap, Kellie Bowen, Robert Place, Long-Cheng Li, Raghu Vemuganti: Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. *J Cereb Blood Flow Metab* 29, 675–687 (2009)

27. Emmette R Hutchison, Eitan Okun, Mark P Mattson: The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair. *Neuromolecular Med* 11, 153–61 (2009)

28. Omar F Laterza, Lee Lim, Philip W Garrett-Engele, Katerina Vlasakova, Nagaraja Muniappa, Wesley K Tanaka, Jason M Johnson, Joseph F Sina, Thomas L Fare, Frank D Sistare, Warren E Glaab: Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. *Clin Chem* 55, 1977–83 (2009)

29. Da-Zhi Liu, Yingfang Tian, Bradley P Ander, Huichun Xu, Boryana S Stamova, Xinhua Zhan, Renee J Turner, Glen Jickling, Frank R Sharp: Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. *J Cereb Blood Flow Metab* 2009 Sep 2

30. Emmette R Hutchison, Eitan Okun, Mark P Mattson: Expression profile of MicroRNAs in young stroke patients. *PLoS One* 4, e7689 (2009)

31. Isaac W Boss, Karlie B Plaisance, Rolf Renne: Role of virus-encoded microRNAs in herpesvirus biology. *Trends Microbiol* 2009 Oct 12

32. Rossella Menghini, Viviana Casagrande, Marina Cardellini, Eugenio Martelli, Alessandro Terrinoni, Francesca Amati, Mariuca Vasa-Nicotera, Arnaldo Ippoliti, Giuseppe Novelli, Gerry Melino, Renato Lauro, Massimo Federici: MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. *Circulation* 120, 1524–32 (2009)

33. E Maria C Ohlsson Teague, Cristin G Printz, M Louise Hull: The role of microRNAs in endometriosis and associated reproductive conditions. *Hum Reprod Update* 2009 Sep 22
34. Lai-Sheung Chan, Patrick Ying-Kit Yue, Nai-Ki Mak, Ricky Ngok-Shun Wong: Role of MicroRNA-214 in ginsenoside-Rg1-induced angiogenesis. *Eur J Pharm Sci* 38, 370-7 (2009)
35. Angelika Bonauer, Guillaume Carmona, Masayoshi Iwasaki, Marina Mione, Masamichi Koyanagi, Ariane Fischer, Jana Burchfield, Henrik Fox, Carmen Doebele, Kisho Ohtani, Emmanouil Chavakis, Michael Potente, Marc Tjwa, Carmen Urbich, Andreas M. Zeiher, Stefanie Dimmeler: MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. *Science* 324, 1710-3(2009)
36. Jason E Fish, Deepak Srivastava: MicroRNAs: opening a new vein in angiogenesis research. *Sci Signal* 2, pe1 (2009)
37. John B Redell, Yin Liu, Pramod K Dash: Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes. *J Neurosci Res* 87, 1435-48 (2009)
38. Frank Kuhnert, Michael R Mancuso, Jessica Hampton, Kryn Stankunas, Tomoichiro Asano, Chang-Zheng Chen, Calvin J Kuo: Attribution of vascular phenotypes of the murine Eglf7 locus to the microRNA miR-126. *Development* 135, 3989-93 (2008)
39. Thomas Wurdinger, Bakhos A Tannous, Okay Saydam, Johan Skog, Stephan Grau, Jurgen Soutschek, Ralph Weissleder, Xandra O Breakefield, Anna M Krichevsky: miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. *Cancer Cell* 14, 382-93 (2008)
40. Alberto Izzotti, George A Calin, Patrizio Arrigo, Vernon E Steele, Carlo M Croce, Silvio De Flora: Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. *FASEB J* 23, 806-12 (2009)
41. Qun Pan, Nasser Chegini: MicroRNA signature and regulatory functions in the endometrium during normal and disease states. *Semin Reprod Med* 26, 479-93 (2008)
42. Yajaira Suarez, Carlos Fernandez-Hernando, Jun Yu, Scott A Gerber, Kenneth D Harrison, Jordan S Pober, M Luisa Iruela-Arispe, Matthias Merkenschlager, William C Sessa: Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. *Proc Natl Acad Sci U S A* 105, 14082-7 (2008)
43. Jason E Fish, Massimo M Santoro, Sarah U Morton, Sangho Yu, Ru-Fang Yeh, Joshua D Wythe, Benoit G Bruneau, Didier Y R Stainier, Deepak Srivastava: miR-126 regulates angiogenic signaling and vascular integrity. *Dev Cell* 15, 272-84 (2008)
44. Shusheng Wang, Arin B Aurora, Brett A Johnson, Xiaoxia Qi, John McAnally, Joseph A Hill, James A Richardson, Rhonda Bassel-Duby, Eric N Olson: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Dev Cell* 15, 261-71 (2008)
45. Chunxiang Zhang: MicroRNAs: role in cardiovascular biology and disease. *Clin Sci (Lond)* 114, 699-706 (2008)
46. Joshua T Mendell: miRiad roles for the miR-17-92 cluster in development and disease. *Cell* 133, 217-22 (2008)
47. Zhiguo Wang, Xioabin Luo, Yanjie Lu, Baofeng Yang: miRNAs at the heart of the matter. *J Mol Med* 86, 771-83 (2008)
48. Elizabeth Scalbert, Antoine Bril: Implication of microRNAs in the cardiovascular system. *Curr Opin Pharmacol* 8, 181-8 (2008)
49. R Kulshreshtha, RV Davuluri, GA Calin, M Ivan: A microRNA component of the hypoxic response. *Cell Death Differ* 15, 667-71 (2008)
50. Peter Olson, Jun Lu, Hao Zhang, Anny Shai, Matthew G Chun, Yucheng Wang, Steven K Libutti, Eric K Nakakura, Todd R Golub, Douglas Hanahan: MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. *Genes Dev* 23, 2152-65 (2009)
51. Eun-Mee Lee, Sangsu Shin, Hwa Jun Cha, Youngmin Yoon, Seunghee Bae, Jin Hyuk Jung, Sun-Mi Lee, Su-Jae Lee, In-Chul Park, Young-Woo Jin, Sungkwan An: Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. *Int J Mol Med* 24, 45-50 (2009)
52. Aldo M Roccaro, Antonio Sacco, Brian Thompson, Xavier Leleu, Abdel Kareem Azab, Feda Azab, Judith Runnels, Xiaoying Jia, Hai T Ngo, Molly R Melhem, Charles P Lin, Domenico Ribatti, Barrett J Rollins, Thomas E Witzig, Kenneth C Anderson, Irene M Ghobrial: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. *Blood* 113, 6669-80 (2009)
53. Ferdinando Pucci, Mary Anna Venneri, Daniela Biziato, Alessandro Nonis, Davide Moi, Antonio Sica, Clelia Di Serio, Luigi Naldini, Michele De Palma: A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. *Blood* 114, 901-14 (2009)
54. Sean Lawler, E Antonio Chiocca: Emerging functions of microRNAs in glioblastoma. *J Neurooncol* 92, 297-306 (2009)
55. Wei-Chih Tsai, Paul Wei-Che Hsu, Tsung-Ching Lai, Gar-Yang Chau, Ching-Wen Lin, Chun-Ming Chen, Chien-Der Lin, Yu-Lun Liao, Jui-Ling Wang, Yat-Pang Chau, Ming-Ta Hsu, Michael Hsiao, Hsien-Da Huang, Ann-Ping Tsou: MicroRNA-122, a tumor suppressor microRNA that

regulates intrahepatic metastasis of hepatocellular carcinoma. *Hepatology* 49, 1571-82 (2009)

56. Zhizhong Li, Hui Wang, Christine E Eyler, Anita B Hjelmeland, Jeremy N Rich: Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. *J Biol Chem* 284, 16705-9 (2009)

57. Bo Liu, Xiao-Chun Peng, Xiao-Li Zheng, JunWang, Yong-Wen Qin: MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines *in vitro* and *in vivo*. *Lung Cancer* 66, 169-75 (2009)

58. Laura Gramantieri, Francesca Fornari, Elisa Callegari, Silvia Sabbioni, Giovanni Lanza, Carlo M. Croce, Luigi Bolondi, Massimo Negrini: MicroRNA involvement in hepatocellular carcinoma. *J Cell Mol Med* 12, 2189-204 (2008)

59. Yuan-Hau Tsai, Min-Fen Wu, Yu-Hsuan Wu, Shing-Jyh Chang, Su-Fang Lin, Tyson V Sharp, Hsei-Wei Wang: The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. *J Virol* 83, 622-32 (2009)

60. Hong-Ye Zhao, Akio Ooyama, Masatatsu Yamamoto, Ryuji Ikeda, Misako Haraguchi, Sho Tabata, Tatsuhiko Furukawa, Xiao-Fang Che, Ken-ichi Iwashita, Toshinori Oka, Masakazu Fukushima, Masayuki Nakagawa, Mayumi Ono, Michihiko Kuwano, Shin-ichi Akiyama: Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. *Cancer Lett* 270, 156-63 (2008)

61. Xuenong Zou, Lijin Zou, Ying He, Cody Bunger: Molecular treatment strategies and surgical reconstruction for metastatic bone diseases. *Cancer Treat Rev* 34, 527-38 (2008)

62. Alex Galanis, Aglaia Pappa, Antonis Giannakakis, Evripidis Lanitis, Denarda Dangaj, Raphael Sandaltzopoulos: Reactive oxygen species and HIF-1 signalling in cancer. *Cancer Lett* 266, 12-20 (2008)

63. T Dalmay, DR Edwards: MicroRNAs and the hallmarks of cancer. *Oncogene* 25, 6170-5 (2006)

64. Michael Dews, Asal Homayouni, Duonan Yu, Danielle Murphy, Cinzia Sevigani, Erik Wentzel, Emma E Furth, William M Lee, Greg H Enders, Joshua T Mendell, Andrei Thomas-Tikhonenko: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. *Nat Genet* 38, 1060-5 (2006)

65. Peter M Rothwell: Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke? *Nat Clin Pract Cardiovasc Med* 6, 164-5 (2009)

66. Jordan S Pober, William C Sessa: Evolving functions of endothelial cells in inflammation. *Nat Rev Immunol* 7, 803-815 (2007)

67. Heike Beck, Till Acker, Christoph Wiessner, Peter R Allegrini, Karl H Plate: Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. *Am J Pathol* 157, 1473-1483 (2000)

68. Takeshi Hayashi, Nobuo Noshita, Taku Sugawara, Pak H Chan: Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. *J Cereb Blood Flow Metab* 23, 166-180 (2003)

69. Hugo JH Marti, Myriam Bernaudin, Anita Bellail, Heike Schoch, Monika Euler, Edwige Petit, Werner Risau: Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. *Am J Pathol* 156, 965-976 (2000)

70. Carmen Urbich, Angelika Kuehnbacher, Stefanie Dimmeler: Role of microRNAs in vascular diseases, inflammation, and angiogenesis. *Cardiovasc Res* 79, 581-588 (2008)

71. Tomas Sobrino, Olivia Hurtado, Maria Angeles Moro, Manuel Rodriguez-Yanez, Mar Castellanos, David Brea, Octavio Moldes, Miguel Blanco, Juan F Arenillas, Rogelio Leira, Antonio Davalos, Ignacio Lizasoain, JoseCastillo: The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. *Stroke* 38, 2759-2764 (2007)

72. Hon-Kan Yip, Li-Teh Chang, Wen-Neng Chang, Cheng-Hsien Lu, Chia-Wei Liou, Min-Yu Lan, Josef S. Liu, Ali A. Youssef, Hsueh-Wen Chang: Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. *Stroke* 39, 69-74 (2008)

73. Takayuki Asahara, Atsuhiko Kawamoto: Endothelial progenitor cells for postnatal vasculogenesis. *Am J Physiol Cell Physiol* 287, C572-C579 (2004)

74. Takayuki Asahara, Toyoaki Murohara, Alison Sullivan, Marcy Silver, Rien van der Zee, Tong Li, Bernhard Witzenbichler, Gina Schatteman, Jeffrey M Isner: Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 275, 964-967 (1997)

75. Srinivasulu Chigurupati, Thiruma V Arumugam, Tae Gen Son, Justin D Lathia, Shafaq Jameel, Mohamed R Mughal, Sung-Chun Tang, Dong-Gyu Jo, Simonetta Camandola, Marialuisa Giunta, Irina Rakova, Nazli McDonnell, Lucio Miele, Mark P Mattson, Suresh Poosala: Involvement of notch signaling in wound healing. *PLoS ONE* e1167 (2007)

76. Heike Beck, Karl H Plate: Angiogenesis after cerebral ischemia. *Acta Neuropathol* 117,481-496 (2009)

77. John J Ohab, Sheila Fleming, Armin Blesch, S Thomas Carmichael: A neurovascular niche for neurogenesis after stroke. *J. Neurosci.* 26, 13007-13016 (2006)

78. T Hayashi, K Abe, H Suzuki, Y Itoyama: Rapid induction of vascular endothelial growth factor gene

expression after transient middle cerebral artery occlusion in rats. *Stroke* 28, 2039–2044 (1997)

79. Plate Karl H, Beck Heike, Danner Simone, Allegrini Peter R, Wiessner Christoph: Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. *J Neuropathol Exp Neurol* 58, 654–66 (1999)

80. Tania M Hansen, Andrew J Moss, Nicholas PJ Brindle: Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. *Curr Neurovasc Res* 5, 236–45 (2008)

81. Vincent Laudenbach, Romain H Fontaine, Fadia Medja, Peter Carmeliet, Daniel J Hicklin, Jorge Gallego, Philippe Leroux, Stéphane Marret, Pierre Gressens: Neonatal hypoxic preconditioning involves vascular endothelial growth factor. *Neurobiol Dis* 26, 243–52 (2007)

82. Antje Wick, Wolfgang Wick, Johannes Waltenberger, Michael Weller, Johannes Dichgans, Jorg B Schulz: Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. *J Neurosci* 22, 6401–7 (2002)

83. Akimasa Yano, Tetsuro Shingo, Akira Takeuchi, Takao Yasuhara, Kazuki Kobayashi, Kazuya Takahashi, Kenichiro Muraoka, Toshihiro Matsui, Yasuyuki Miyoshi, Hirofumi Hamada, Isao Date: Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. *J Neurosurg* 103, 104–14 (2005)

84. Charles S Cobbs, Jun Chen, David A Greenberg, Steven H Graham: Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat. *Neurosci Lett* 249, 79–82 (1998)

85. Z Kovacs, K Ikezaki, K Samoto, T Inamura, M Fukui: VEGF and Xt. Expression time kinetics in rat brain infarct. *Stroke* 27, 1865–1872 (1996)

86. Mun-Yong Lee, Won-Kyu Ju, Jung-Ho Cha, Byung Chul Son, Myung-Hoon Chun, Joon Ki Kang, Chun Kun Park: Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats. *Neurosci Lett* 265:107–110 (1999)

87. Fredrik Lennmyr, Khaled Ahmad Ata, Keiko Funa, Yngve Olsson, Andreas Terent: Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. *J Neuropathol Exp Neurol* 57, 874–882 (1998)

88. Eberhard Gunsilius, Andreas L Petzer, Gunther Stockhammer, Christian M. Kähler, Gunther Gastl: Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. *Stroke* 32:275–b (2001)

89. R Issa, J Krupinski, T Bujny, S Kumar, J Kaluza, P Kumar: Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. *Lab Invest* 79:417–425 (1999)

90. M Slevin, J Krupinski, A Slowik, P Kumar, A Szczudlik, J Gaffney: Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. *Stroke* 8, 1863–1870 (2000)

91. Daniel J Hicklin, Lee M Ellis: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol* 23, 1011–1027 (2005)

92. Zheng Gang Zhang, Li Zhang, Quan Jiang, Ruilan Zhang, Kenneth Davies, Cecylia Powers, Nicholas van Bruggen, Michael Chopp: VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. *J Clin Invest* 106: 829–38, 2000.

93. Sarah Kay Harten, Margaret Ashcroft, Patrick Henry Maxwell: prolyl hydroxylase domain (PHD) inhibitors: a route to hif activation & neuroprotection. *Antioxid Redox Signal* 2009 Sep 8.

94. Teng-Nan Lin, Chien-Kai Wang, Wai-Mui Cheung, Chung-Yi Hsu: Induction of angiopoietin and Tie receptor mRNA expression after cerebral ischemia-reperfusion. *J Cereb Blood Flow Metab* 20, 387–395 (2000)

95. Zheng Gang Zhang, Li Zhang, Quan Jiang, Michael Chopp: Bone marrowderived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. *Circ Res* 90, 284–288(2002)

96. Zhenggang Zhang, Michael Chopp: Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. *Trends Cardiovasc Med* 12, 62–66 (2002)

97. Zheng Gang Zhang, Li Zhang, Wayne Tsang, Hamid Soltanian-Zadeh, Daniel Morris, Ruilan Zhang, Anton Goussev, Cecylia Powers, Thomas Yeich, Michael Chopp: Correlation of VEGF and angiopoietin expression with disruption of bloodbrain barrier and angiogenesis after focal cerebral ischemia. *J Cereb Blood Flow Metab* 22, 379–392 (2002)

98. Nicholas W Gale, Gavin Thurston, Sean F Hackett, Roumiana Renard, Quan Wang, Joyce McClain, Cliff Martin, Charles Witte, Marlys H Witte, David Jackson, Chitra Suri, Peter A Campochiaro, Stanley J Wiegand, George D Yancopoulos: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. *Dev Cell* 3, 411–423 (2002)

99. Zheng Gang Zhang, Michael Chopp, Dunyue Lu, Tsang Wayne, Rui Lan Zhang, Daniel Morris: Receptor tyrosine kinase tie 1 mRNA is upregulated on cerebral

microvessels after embolic middle cerebral artery occlusion in rat. *Brain Res* 847, 338–342 (1999)

100. Teng-nan Lin, Gau-ming Nian, Shu-fen Chen, Wai-mui Cheung, Chen Chang, Wen-chang Lin, Chung Y Hsu: Induction of Tie-1 and Tie-2 receptor protein expression after cerebral ischemia-reperfusion. *J Cereb Blood Flow Metab* 21, 690–701 (2001)

101. AA Qutub, F Gabhann Mac, ED Karagiannis, P Vempati, AS Popel: Multiscale models of angiogenesis. *IEEE Eng Med Biol Mag* 28, 14–31 (2009)

102. Gregg L Semenza: Hydroxylation of HIF-1: Oxygen sensing at the molecular level. *Physiology* 19, 176–182 (2004)

103. Frank L Powell: Functional genomics and the comparative physiology of hypoxia. *Annu. Rev. Physiol* 65, 203–230 (2003)

104. Ritu Kulshreshtha, Manuela Ferracin, Sylwia E. Wojcik, Ramiro Garzon, Hansjuerg Alder, Francisco J Agosto-Perez, Ramana Davuluri, Chang-Gong Liu, Carlo M Croce, Massimo Negrini, George A Calin, Mircea Ivan: A microRNA signature of hypoxia. *Mol Cell Biol* 27, 1859–1867 (2007)

105. TL Haas, M Milkiewicz, SJ Davis, AL Zhou, S Egginton, MD Brown, JA Madri, O Hudlicka: Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. *Am. J. Physiol. Heart Circ. Physiol.* 279, H1540–H1547 (2000)

106. Tae-Hwa Chun, Farideh Sabeh, Ichiro Ota, Hedwig Murphy, Kevin T McDonagh, Kenn Holmbeck, Henning Birkedal-Hansen, Edward D Allen, Stephen J Weiss: MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. *J. Cell Biol.* 167, 757–767 (2004)

107. Chanhung Z Lee, Zheng Xue, Qi Hao, Guo-Yuan Yang, William L Young: Nitric oxide in vascular endothelial growth factor-induced focal angiogenesis and matrix metalloproteinase-9 activity in the mouse brain. *Stroke* 40, 2879–81 (2009)

108. Shay Soker, Hua-Quan Miao, Masashi Nomi, Seiji Takashima, Michael Klagsbrun: VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. *J. Cell. Biochem* 85, 357–368 (2002)

109. Feilim Mac Gabhann, Aleksander S Popel : Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin *in vivo*: A computational model of human skeletal muscle. *Am. J. Physiol. Heart Circ. Physiol.* 292, H459–H474 (2007)

110. Zheng Gang Zhang, Wayne Tsang, Li Zhang, Cecylia Powers, Michael Chopp: Up-regulation of neuropilin-1 in neovasculature after focal cerebral ischemia

in the adult rat. *J Cereb Blood Flow Metab* 21, 541–549 (2001)

111. Beck Heike, Acker Till, Puschel Andreas W, Fujisawa Hajime, Carmeliet Peter, Plate Karl H: Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. *J Neuropathol Exp Neurol* 61, 339–350 (2002)

112. M Digicaylioglu, S Bichet, H H Marti, R H Wenger, L A Rivas, C Bauer, M Gassmann: Localization of specific erythropoietin binding sites in defined areas of the mouse brain. *Proc Natl Acad Sci USA* 92, 3717–3720 (1995)

113. Hugo H Marti, Roland H Wenger, Luis A Rivas, Urs Straumann, Murat Oigicaylioglu, Volker Henn, Yasuhiro Yonekawa, Christian Bauer, Max Gassmann : Erythropoietin gene expression in human, monkey and murine brain. *Eur J Neurosci* 8, 666–676 (2006)

114. CC Tan, KU Eckardt, JD Firth, PJ Ratcliffe: Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. *Am J Physiol* 263, F474–F481 (1992)

115. Myriam Bernaudin, Hugo H Marti, Simon Roussel, Didier Divoux, Andre Nouvelot, Eric T MacKenzie, Edwige Petit: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. *J Cereb Blood Flow Metab* 19, 643–651 (1999)

116. R Hambrecht, V Adams, S Erbs, A Linke, N Krankel, Y Shu, Y Baither, S Gielen, H Thiele, JF Gummert, FW Mohr, G Schuler: Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. *Circulation* 107, 3152–3158 (2003)

117. Georg Kojda, Yian C Cheng, Jana Burchfield, David G Harrison: Dysfunctional regulation of endothelial nitric oxide synthase (eNOS) expression in response to exercise in mice lacking one eNOS gene. *Circulation* 103, 2839–2844 (2001)

118. Karen Gertz, Josef Priller, Golo Kronenberg, Klaus B Fink, Benjamin Winter, Helmut Schröck, Shengbo Ji, Milan Milosevic, Christoph Harms, Michael Bohm, Ulrich Dirnagl, Ulrich Laufs, Matthias Endres: Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. *Circ Res* 99, 1132–1140 (2006)

119. F Locatelli, A Bersano, E Ballabio, S Lanfranconi, D Papadimitriou, S Strazzer, N Bresolin, GP Comi, S Corti: Stem cell therapy in stroke. *Cell Mol Life Sci* 66, 757–772 (2009)

120. Arnold I Caplan, James E Dennis: Mesenchymal stem cells as trophic mediators. *J Cell Biochem* 98, 1076–1084 (2006)

121. Rosalind C Lee, Rhonda L Feinbaum, Victor Ambros: The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* 75, 843–854 (1993)
122. Bruce Wightman, Ilho Ha, Gary Ruvkun: Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell* 75, 855–862 (1993)
123. Angelika Kuehbachner, Carmen Urbich, Andreas M Zeiher, Stefanie Dimmeler: Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. *Circ Res* 101, 59–68 (2007)
124. Yajaira Suarez, Carlos Fernandez-Hernando, Jordan S Pober, William C Sessa: Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. *Circ Res* 100, 1164–1173 (2007)
125. Laura Poliseno, Andrea Tuccoli, Laura Mariani, Monica Evangelista, Lorenzo Citti, Keith Woods, Alberto Mercatanti, Scott Hammond, Giuseppe Rainaldi : MicroRNAs modulate the angiogenic properties of HUVECs. *Blood* 108, 3068–3071 (2006)
126. Richard I Gregory, Kai-ping Yan, Govindasamy Amuthan, Thimmaiah Chendrimada, Behzad Doratotaj, Neil Cooch, Ramin Shiekhattar: The microprocessor complex mediates the genesis of microRNAs. *Nature* 432, 235–240 (2004)
127. Markus T Bohnsack, Kevin Czapinski, Dirk Gorlich: Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. *RNA* 10, 185–191 (2004)
128. Yoontae Lee, Kipyoun Jeon, Jun-tae Lee, Sun-young Kim, V Narry Kim: MicroRNA maturation: stepwise processing and subcellular localization. *EMBO J* 21, 4663–4670 (2002)
129. Zissimos Mourelatos, Josee Dostie, Sergey Paushkin, Anup Sharma, Bernard Charroux, Linda Abel, Juri Rappsilber, Matthias Mann, Gideon Dreyfuss: miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. *Genes Dev* 16, 720–728 (2002)
130. Gyorgy Hutvagner, Phillip D Zamore: A microRNA in a multiple-turnover RNAi enzyme complex. *Science* 297, 2056–2060 (2002)
131. Alla Grishok, Amy E Pasquinelli, Darryl Conte, Na Li, Susan Parrish, Ilho Ha, David L Baillie, Andrew Fire, Gary Ruvkun, Craig C Mello: Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control *C. elegans* developmental timing. *Cell* 106, 23–34 (2001)
132. Rene F Ketting, Sylvia EJ Fischer, Emily Bernstein, Titia Sijen, Gregory J Hannon, Ronald HA Plasterk: Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev* 15, 2654–2659 (2001)
133. Gyorgy Hutvagner, Juanita McLachlan, Amy E Pasquinelli, Eva Balint, Thomas Tuschl, Phillip D Zamore: A cellular function for the RNA-interference enzyme Dicer in the maturation of the *let-7* small temporal RNA. *Science* 293, 834–838 (2001)
134. Andreas Lingel, Bernd Simon, Elisa Izaurralde, Michael Sattler: Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain. *Nature* 426, 465–469 (2003)
135. Ramesh S Pillai, Suvendra N Bhattacharyya, Witold Filipowicz: Repression of protein synthesis by miRNAs: how many mechanisms? *Trends Cell Biol* 17, 118–126 (2007)
136. Gunter Meister, Thomas Tuschl: Mechanisms of gene silencing by double-stranded RNA. *Nature* 431, 343–349 (2004)
137. Wei Wu, Miao Sun, Gang-Ming Zou, Jianjun Chen: MicroRNA and cancer: current status and prospective. *Int J Cancer* 120, 953–960 (2007)
138. Angelika Kuehbachner, Carmen Urbich, Stefanie Dimmeler: Targeting microRNA expression to regulate angiogenesis. *Trends Pharmacol Sci* 29, 12–15 (2008)
139. Lin He, Gregory J Hannon: MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 5, 522–531 (2004)
140. Yoontae Lee, Chiyoung Ahn, Jinju Han, Hyounjeong Choi, Jaekwang Kim, Jeongbin Yim, Junho Lee, Patrick Provost, Olof Radmark, Sunyoung Kim, V Narry Kim: The nuclear RNase III Drosha initiates microRNA processing. *Nature* 425, 415–419 (2003)
141. Wei J Yang, Derek D Yang, Songqing Na, George E Sandusky, Qing Zhang, Genshi Zhao: Dicer is required for embryonic angiogenesis during mouse development. *J Biol Chem* 280:9330–9335 (2005)
142. Shani Shilo, Sashwati Roy, Savita Khanna, Chandan K Sen: Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells. *Arterioscler Thromb Vasc Biol* 28, 471–477 (2008)
143. George Adrian Calin, Calin Dan Dumitru, Masayoshi Shimizu, Roberta Bichi, Simona Zupo, Evan Noch, Hansjuerg Alder, Sashi Rattan, Michael Keating, Kanti Rai, Laura Rassenti, Thomas Kipps, Massimo Negrini, Florencia Bullrich, and Carlo M. Croce: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 99, 15524–15529 (2002)
144. Zhong Hua, Qing Lv, Wenbin Ye, Chung-Kwun Amy Wong, Guoping Cai, Dayong Gu, Yanhong Ji, Chen Zhao,

Jifeng Wang, Burton B. Yang, Yaou Zhang: MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. *PLoS ONE* 1, e116 (2009)

145. Amelia Cimmino, George Adrian Calin, Muller Fabbri, Marilena V Iorio, Manuela Ferracin, Masayoshi Shimizu, Sylwia E Wojcik, Rami I Aqeilan, Simona Zupo, Mariella Dono, Laura Rassenti, Hansjuerg Alder, Stefano Volinia, Chang-gong Liu, Thomas J. Kipps, Massimo Negrini, Carlo M Croce: miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci U S A* 102, 13944–13949 (2005)

146. Peter S Linsley, Janell Schelter, Julja Burchard, Miho Kibukawa, Melissa M Martin, Steven R Bartz, Jason M Johnson, Jordan M Cummins, Christopher K Raymond, Hongyue Dai, Nelson Chau, Michele Cleary, Aimee L Jackson, Michael Carleton, Lee Lim: Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. *Mol Cell Biol* 27, 2240–2252 (2007)

147. Motoyuki Otsuka, Min Zheng, Masaaki Hayashi, Jing-Dwan Lee, Osamu Yoshino, Shengcai Lin, Jiahui Han: Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. *J Clin Invest* 118, 1944–1954 (2008)

148. Andrea Ventura, Amanda G Young, Monte M Winslow, Laura Lintault, Alex Meissner, Stefan J Erkeland, Jamie Newman, Roderick T Bronson, Denise Crowley, James R Stone, Rudolf Jaenisch, Phillip A Sharp, Tyler Jacks: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* 132, 875–886 (2008)

149. Jennifer A Chan, Anna M Krichevsky, Kenneth S Kosik: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. *Cancer Res* 65, 6029–6033 (2005)

150. Angie M Cheng, Mike W Byrom, Jeffrey Shelton, Lance P Ford: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. *Nucleic Acids Res* 33, 1290–1297 (2005)

151. Peggy S Eis, Wayne Tam, Liping Sun, Amy Chadburn, Zongdong Li, Mario F Gomez, Elsebet Lund, James E Dahlberg: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. *Proc Natl Acad Sci U S A* 102, 3627–3632 (2005)

152. Stefano Volinia, George A Calin, Chang-Gong Liu, Stefan Ambs, Amelia Cimmino, Fabio Petrocchi, Rosa Visone, Marilena Iorio, Claudia Roldo, Manuela Ferracin, Robyn L Prueitt, Nozumu Yanaihara, Giovanni Lanza, Aldo Scarpa, Andrea Vecchione, Massimo Negrini, Curtis C Harris, Carlo M Croce: A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci U S A* 103, 2257–2261 (2006)

153. Reinhard Waehler, Stephen J Russell, David T Curiel: Engineering targeted viral vectors for gene therapy. *Nature Rev Genet* 8, 573–587 (2007)

154. Ruirui Ji, Yunhui Cheng, Junming Yue, Jian Yang, Xiaojun Liu, He Chen, David B. Dean, Chunxiang Zhang: MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. *Circ Res* 100, 1579–1588 (2007)

155. Tamia A Harris, Munekazu Yamakuchi, Marcella Ferlito, Joshua T Mendell, Charles J Lowenstein: MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. *Proc Natl Acad Sci U S A* 105, 1516–1521 (2008)

156. Luisa Campagnolo, Amy Leahy, Smita Chitnis, Stefan Koschnick, Michael J Fitch, John T Fallon, David Loskutoff, Mark B Taubman, Heidi Stuhlmann: EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. *Am J Pathol* 167, 275–284 (2005)

157. Fabrice Soncin, Virginie Mattot, Frederic Lionneton, Nathalie Spruyt, Frederic Lepretre, Agnes Begue, Dominique Stehelin: VE-statin, an endothelial repressor of smooth muscle cell migration. *EMBO J* 22, 5700–5711 (2003)

158. Mariana Lagos-Quintana, Reinhard Rauhut, Abdullah Yalcin, Jutta Meyer, Winfried Lendeckel, Thomas Tuschl: Identification of tissue-specific microRNAs from mouse. *Curr Biol* 12, 735–739 (2002)

159. Erno Wienholds, Wigard P Kloosterman, Eric Miska, Ezequiel Alvarez-Saavedra, Eugene Berezikov, Ewart de Bruijn, H Robert Horvitz, Sakari Kauppinen, Ronald HA Plasterk: MicroRNA expression in zebrafish embryonic development. *Science* 309, 310–311 (2005)

160. Libero Santarpi, Milena Nicoloso, George Calin: MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. *Endocr Relat Cancer* 2009 Oct 20

161. Yajaira Suarez, William C Sessa: MicroRNAs as novel regulators of angiogenesis. *Circ Res* 104, 442–54 (2009)

162. Yun Chen, David H Gorski: Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. *Blood* 111, 1217–1226 (2008)

163. Christopher W Pugh, Peter J Ratcliffe: Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med* 9, 677–684 (2003)

164. Pasquale Fasanaro, Yuri D'Alessandra, Valeria Di Stefano, Roberta Melchionna, Sveva Romani, Giulio Pompilio, Maurizio C Capogrossi, Fabio Martelli: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. *J Biol Chem* 283, 15878–15883 (2008)

165. Michele De Palma, Eugenio Montini, Francesca R Santoni de Sio, Fabrizio Benedicenti, Alessandra Gentile, Enzo Medico, Luigi Naldini: Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. *Blood* 105, 2307–2315 (2005)
166. A Papapetropoulos, G García-Cardena, J A Madri, W C Sessa: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. *J Clin Invest* 100, 3131–3139 (1997)
167. Carlos le Sage, Remco Nagel, David A Egan, Mariette Schrier, Elly Mesman, Annunziato Mangiola, Corrado Anile, Giulio Maira, Neri Mercatelli, Silvia Anna Ciafre, Maria Giulia Farace, Reuven Agami: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. *EMBO J* 26, 3699–3708 (2007)
168. Gustavo Baldassarre, Barbara Belletti, Milena S Nicoloso, Monica Schiappacassi, Andrea Vecchione, Paola Spessotto, Andrea Morrione, Vincenzo Canzonieri, Alfonso Colombatti: p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. *Cancer Cell* 7, 51-63 (2005)
169. Isabel M Chu, Ludger Hengst, Joyce M Slingerland: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. *Nature Reviews Cancer* 8, 253-267 (2008)
170. Daniel Y Lee, Zhaoqun Deng, Chia-Hui Wang, Burton B Yang: MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. *Proc Natl Acad Sci* 104, 20350–20355 (2007)
171. Wigard P Kloosterman, Anne K Lagendijk, ReneF Ketting, Jon D Moulton, Ronald HA Plasterk: Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. *PLoS Biol* 5, e203 (2007)
172. Jan Krutzfeldt, Nikolaus Rajewsky, Ravi Braich, Kallanthottathil G Rajeev, Thomas Tuschl, Muthiah Manoharan, Markus Stoffel: Silencing of microRNAs *in vivo* with “antagomirs”. *Nature* 438, 685-689 (2005)
173. Joacim Elmen, Morten Lindow, Asli Silahtaroglu, Mads Bak, Mette Christensen, Allan Lind-Thomsen, Maj Hedtjarn, Jens Bo Hansen, Henrik Frydenlund Hansen, Ellen Marie Straarup, Keith McCullagh, Phil Kearney, Sakari Kauppinen: Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. *Nucl Acids Res* 36, 1153-1162 (2008)
174. Joacim Elmen, Morten Lindow, Sylvia Schutz, Matthew Lawrence, Andreas Petri, Susanna Obad, Marie Lindholm, Maj Hedtjarn, Henrik Frydenlund Hansen, Urs Berger, Steven Gullans, Phil Kearney, Peter Sarnow, Ellen Marie Straarup, Sakari Kauppinen: LNA-mediated microRNA silencing in non-human primates. *Nature* 452, 896–899 (2008)
175. Christine Esau, Scott Davis, Susan F Murray, Xing Xian Yu, Sanjay K Pandey, Michael Pear, LynnettaWatts, Sheri L Booten, Mark Graham, Robert McKay, Amuthakannan Subramaniam, Stephanie Propp, Bridget A Lollo, Susan Freier, C Frank Bennett, Sanjay Bhanot, Brett P Monia: miR-122 regulation of lipid metabolism revealed by *in vivo* antisense targeting. *Cell Metab* 3, 87–98 (2006)
176. Alessandra Care, Daniele Catalucci, Federica Felicetti, Desiree Bonci, Antonio Addario, Paolo Gallo, Marie-Louise Bang, Patrizia Segnalini, Yusu Gu, Nancy D Dalton, Leonardo Elia, Michael V G Latronico, Morten Høydal, Camillo Autore, Matteo A Russo, Gerald W Dorn2, Oyvind Ellingsen, Pilar Ruiz-Lozano, Kirk L Peterson, Carlo M Croce, Cesare Peschle, Gianluigi Condorelli: MicroRNA-133 controls cardiac hypertrophy. *Nature Med* 13, 613–618 (2007)
177. Desiree Bonci, Valeria Coppola, Maria Musumeci, Antonio Addario, Raffaella Giuffrida, Lorenzo Memeo, Leonardo D’Urso, Alfredo Pagliuca, Mauro Biffoni, Catherine Labbaye, Monica Bartucci, Giovanni Muto, Cesare Peschle, Ruggero De Maria: The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. *Nature Med* 14, 1271–1277 (2008)
178. Takeshi Haraguchi, Yuka Ozaki and Hideo Iba: Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. *Nucleic Acids Res* 37, e43 (2009)
179. Margaret S Ebert, Joel R Neilson, Phillip A Sharp: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. *Nature Methods* 4, 721–726 (2007)
180. Danish Sayed, Shweta Rane, Jacqueline Lypowy, Minzhen He, Ieng-Yi Chen, Himanshu Vashistha, Lin Yan, Ashwani Malhotra, Dorothy Vatner, Maha Abdellatif: MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. *Mol Biol Cell* 19, 3272–3282 (2008)
181. Scott Davis, Bridget Lollo, Susan Freier, Christine Esau: Improved targeting of miRNA with antisense oligonucleotides. *Nucleic Acids Res* 34, 2294 –2304 (2006)
182. Z Lu, M Liu, V Stribinskis, CM Klinge, KS Ramos, NH Colburn, Y Li: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. *Oncogene* 27, 4373-4379 (2008)
183. Jiening Xiao, Baofeng Yang, Huixian Lin, Yanjie Lu, Xiaobin Luo, Zhiguo Wang: Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. *J Cell Physiol* 212, 285–292 (2007)
184. Marc Schmidt-Supprian, Klaus Rajewsky: Vagaries of conditional gene targeting. *Nat Immunol* 8, 665–668 (2007)

Abbreviations: VEGF: vascular endothelial growth factor; HIF1: Hypoxia-inducible factor 1; MMPs: matrix metalloproteinases; GAX: growth arrest homeobox; Egfl7: EGF-like domain 7.

Key Words: MicroRNA, Angiogenesis, Stroke, Cerebral Ischemia, Review

Send correspondence to: Yanqin Gao, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200032, China, Tel: 86-21-54237395, Fax: 86-21-64224778, E-mail: yanqin.gao@gmail.com

<http://www.bioscience.org/current/vol2E.htm>